Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

The study results “indicate that the public has certain reservations about the integration of AI in health care,” the researchers wrote.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Resources available to clinical research physicians and the expectations placed upon these individuals vary across cancer cancers, data suggest.

This analysis indicates that proposed Medicaid reforms would have far-reaching consequences beyond federal budget savings, including negative health outcomes, economic losses, and health care system ...

Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

The FDA has approved once-monthly dosing of Elrexfio (elranatamab-bcmm) for certain patients with relapsed or refractory multiple myeloma.

Researchers assessed the global burden of breast cancer in boys and men aged 15-64 years between 1990 and 2021.

The Trump administration’s immigration policies are having negative effects on health care, impacting patients and health care workers alike.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.